- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06061536
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
A Randomized, Controlled, Open-label, Dose-exploration Study to Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients Who Have Not Received Antiviral Treatment Before.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
multiple sites, randomized, open-label, controlled study design. 64 eligible subjects will be enrolled in this study, and they will be randomly assigned to each group in a 1:1:1:1 proportion, 16 subjects in each group. Each site will compete to enroll subjects.
The 4 groups are as follows: Group A:Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily); Group B:Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily); Group C:Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily); Group D:DTG +3TC + TDF(once daily).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ping Ma, Doctor
- Phone Number: +8615922124490
- Email: mapingtianjin@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Tianjin Second People's Hospital
-
Contact:
- Ping Ma, Doctor
- Phone Number: +8615922124490
- Email: mapingtianjin@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age≥18 years (including the critical value) when signed the informed consent form ,.male or female.
- Untreated, confirmed HIV-1 infected patients;
- HIV RNA viral load≥1000 copies/mL;
- CD4+ T cell counts≥200 cells/mm3;
- Subjects who have no plans for conception within the 2 weeks prior to screening and 3 months after the end of the trial, and who agree to use effective non-pharmacological contraceptive measures during the trial;
- Sign informed consent prior to the test and fully understand the purpose, nature, methods, and possible adverse reactions, and be willing to participate in the study.
Exclusion Criteria:
- Subjects with an allergy history or hypersensitivity to any component or excipient of the investigational drug;
- Subjects with severe opportunistic infections or opportunistic tumors;
- Subjects with confirmed AIDS or in the acute infection stage;
- Hepatitis B virus surface antigen (HBsAg)/hepatitis C virus antibody (HCV-Ab) Positive;
- ALT and/or AST≥5×ULN;
- ALT≥3×ULN and total bilirubin≥2×ULN (direct bilirubin/total bilirubin>35%;
- GFR<70ml/min/1.73m2 (estimated from creatinine values based on the CKD-EPI Creatinine 2009 Equation), or creatinine ≥ULN;
- Subjects with severe and uncontrolled chronic diseases, metabolic diseases, neurological and psychiatric diseases;
- Subjects with a pancreatitis disease history ever before;
- Subjects who are pregnant or lactating women;
- Subjects with a history of drug abuse, alcoholism, or substance misuse;
- Any clinical trials in the 3 months prior to the screening of the trial; 13)Subjects may not be able to complete this study or other investigators' judgment for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A:Lipovirtide 10mg+3TC+TDF
Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily)
|
Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);
Other Names:
|
Experimental: Group B:Lipovirtide 40mg+3TC+TDF
Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily)
|
Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);
Other Names:
|
Experimental: Group C:Lipovirtide 60mg+3TC+TDF
Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily)
|
Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily);
Other Names:
|
Experimental: Group D:DTG +3TC + TDF
DTG +3TC + TDF(once daily)
|
DTG +3TC + TDF(once daily).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV-1 RNA <50 copies/ml
Time Frame: at Day 169 after receiving Lipovirtide administration.
|
The proportion of subjects with HIV-1 RNA <50 copies/ml at Day 169 after receiving Lipovirtide administration.
|
at Day 169 after receiving Lipovirtide administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV-1 RNA <50 copies/ml
Time Frame: at Day 29、Day 85、Day 169 after receiving Lipovirtide administration
|
The proportion of subjects with HIV-1 RNA <50 copies/ml at Day 29、Day 85、Day 169 after receiving Lipovirtide administration
|
at Day 29、Day 85、Day 169 after receiving Lipovirtide administration
|
HIV-1 RNA <400 copies/ml
Time Frame: at Day 85、Day 169 after receiving Lipovirtide administration
|
The proportion of subjects with HIV-1 RNA <400 copies/ml at Day 85、Day 169 after receiving Lipovirtide administration
|
at Day 85、Day 169 after receiving Lipovirtide administration
|
CD4+ T-cell and CD8+ T-cell
Time Frame: at Day 85 and Day 169 after receiving Lipovirtide administration
|
The changes in CD4+ T-cell and CD8+ T-cell counts compared to baseline at Day 85 and Day 169 after receiving Lipovirtide administration
|
at Day 85 and Day 169 after receiving Lipovirtide administration
|
HIV-1 RNA <50 copies/ml
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
The time required to achieve viral suppression (HIV-1 RNA <50 copies/ml)
|
Within Day 169 of after receiving Lipovirtide administration
|
HIV-1 RNA
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
The temporal changes in log-transformed HIV-1 RNA levels compared to baseline
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in respiration rate of Vital Signs
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Respiration rate in times / minute
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in blood pressure of Vital Signs
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Blood pressure in mmHg
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in body temperature of Vital Signs
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Body temperature in Celsius degree
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in ECG PR intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in ECG QRS intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in ECG QT intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in Blood lactate of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of blood lactate will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in Pregnancy test of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Pregnancy test will be tested in female subjects
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in red blood cell count of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Red blood cell count in whole blood is reported in the form of number
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in white blood cell count of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
White blood cell count in whole blood is reported in the form of number
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in neutrophil count of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Neutrophil count in whole blood is reported in the form of number
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in lymphocyte count of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Lymphocyte count in whole blood is reported in the form of number
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in platelet count of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Platelet count in whole blood is reported in the form of number.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in hemoglobin of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in PT of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Prothrombin time (PT) is a screening test for exogenous coagulation factors
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in INR of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in APTT of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of total bilirubin concentration (μmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in direct bilirubin of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in ALT of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of ALT concentration (U/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in AST of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of AST concentration (U/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in total protein of Laboratory Examination.
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of total protein concentration (g/L) in serum will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in albumin of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of albumin concentration (g/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in creatinine of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of creatinine concentration (μmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in glucose of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of glucose concentration (mmol/L) in serum will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in potassium of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of potassium concentration (mmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in sodium of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of sodium concentration (mmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in chlorine of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of chlorine concentration (mmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine specific gravity of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine specific gravity will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine pH of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine pH value will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine glucose of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine glucose will be examined by qualitative test (positive or negative
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine protein of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine protein will be examined by qualitative test (positive or negative
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine ketone body of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine ketone body will be examined by qualitative test (positive or negative).
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine white blood cell of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of white blood cell in urine will be examined by qualitative test (positive or negative).
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in urine occult blood of Laboratory Examination.
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of urine occult blood will be examined by qualitative test (positive or negative)
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in LDH of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of LDH concentration (U/L) in serum will be recorded.
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in Triglyceride of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of Triglyceride concentration (mmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in ALP of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of ALP concentration (U/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Changes from baseline in CHOL of Laboratory Examination
Time Frame: Within Day 169 of after receiving Lipovirtide administration
|
Changes of CHOL concentration (mmol/L) in serum will be recorded
|
Within Day 169 of after receiving Lipovirtide administration
|
Collaborators and Investigators
Investigators
- Study Director: Ping Ma, Doctor, Tianjin Second People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SXKB-LP-80-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Lipovirtide 10mg
-
Shanxi Kangbao Biological Product Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompleted
-
Shanxi Kangbao Biological Product Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Dong-A ST Co., Ltd.Completed
-
Vigonvita Life SciencesCompletedErectile DysfunctionChina
-
Yokohama City UniversityRecruiting
-
International University of Health and WelfareTerminated
-
Eisai Inc.CompletedRenal ImpairmentUnited States
-
Eisai Inc.Completed
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of